ClinicalTrials.gg
Not yet recruitingNCT06171516ICBTUpdated Jul 11, 2024

Internet-based Cognitive Behavioral Therapy for Individuals With Gambling Disorder in Indonesia

An interventional study of iCBT in Gambling, sponsored by Indonesia University. Not yet recruiting. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Indonesia University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 59 Years
Sex
All
01

Study summary

Gambling disorder (GD) has become a wide concern in Indonesia, as many negative consequences aroused from this psychiatric condition. Prompt treatment with appropriate method of delivery is required to achieve optimal outcome in GD patients. This study aims to determine the effectiveness and feasibility of internet-based cognitive behavioral therapy (iCBT) in treating GD.

This non-randomised pilot and feasibility study will recruit 20 people with GD. All participants will receive the iCBT intervention through self-learning videos and guided weekly group sessions. The effectiveness of the intervention will be assessed at baseline (week 0), post-treatment completion (week 10), and 6 weeks post-treatment (week 16).

Expanded access of the iCBT module will not be available until after the study completion.

02

Conditions studied

  • Gambling

Browse trials for

03

In context

Gambling

158 studies on the registry are indexed under Gambling; 42 are open to participants now.

This study's planned enrollment of 20 is below the median of 66 across 128 interventional studies indexed under Gambling.

Browse Gambling studies →

Lead sponsor

Indonesia University is the lead sponsor of 446 studies on the registry; 56 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be aged 18-59 years old;
  • be screened as probable pathological gambler based on South Oaks Gambling Screen (SOGS);
  • have access to electronic devices (ie, smartphone, mobile tablet, personal computer) with internet connection;
  • be proficient in Indonesian language;
  • have agreed to take part in the study by filling out the form.

Exclusion criteria

Exclusion Criteria:

  • have severe mental disorders or intellectual disabilities;
  • have extreme agitation that hinder instrument fill out and adequate cognitive behavior therapy participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Internet-based Cognitive Behavioral Therapy

    10 guided therapy sessions (once-weekly) with each session lasting 20 minutes.

    Behavioral: iCBT

Interventions

  • BehavioraliCBT

    All participants will undergo 10 guided therapy sessions (once-weekly) with each session lasting 20 minutes. The therapy module will be given as an online self-learning source via videos in a website specifically developed for this training. The videos will divide the module content into several parts with each video lasting about 10 minutes.

06

What researchers measure

Primary outcomes

  1. Gambling symptom severity

    a decrease in Gambling Symptom Assessment Scale (G-SAS) score

    Time frame: G-SAS will be assessed at baseline (week 0), post-treatment (week 6), and follow-up (week 16)

  2. Problem gambling severity

    a decrease in Problem Gambling Severity Index score

    Time frame: PGSI will be assessed at baseline (week 0), post-treatment (week 6), and follow-up (week 16)

  3. Gambling urges

    a decrease in Gambling Urge Scale (GUS) score

    Time frame: GUS will be assessed at baseline (week 0), post-treatment (week 6), and follow-up (week 16)

  4. Gambling-related cognitive distortions

    a decrease in Gambling Related Cognitions Scale (GRCS) score

    Time frame: GRCS will be assessed at baseline (week 0), post-treatment (week 6), and follow-up (week 16)

Secondary outcomes

  1. Nonspecific psychological distress

    a decrease in Self Rating Questionnaire-20 (SRQ-20) score

    Time frame: SRQ-20 will be assessed at baseline (week 0), post-treatment (week 6), and follow-up (week 16)

  2. Subjective quality of life

    an increase in World Health Organization Quality-of-Life Scale (WHOQOL-BREF) score

    Time frame: WHOQOL-BREF will be assessed at baseline (week 0), post-treatment (week 6), and follow-up (week 16)

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06171516
Collaborators
Flinders University
Responsible party
Kristiana Siste (Dr. dr. Kristiana Siste, SpKJ(K) - Head of Department of Psychiatry, Faculty of Medicine, Indonesia University, Indonesia University) — Principal investigator
First posted
Dec 14, 2023
Start date
Aug 2024 (estimated)
Primary completion
Nov 2024 (estimated)
Completion
Jan 2025 (estimated)
Last update
Jul 11, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion